← ANALYST RATINGS · TIPRANKS
CG Oncology, Inc. (CGON): analyst forecast and price target
Analyst consensus
Strong Buy9 Buy0 Hold0 Sell
Ratings of 9 analysts in the last 3 months · top analysts only12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $93.12, the highest $108, the lowest $79.00. The average is +55.6% from the last price of $59.85.
Analyst ratings 16
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $67.00 → $65.00−3.0% | Hold | +8.6% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $65.00 → $63.00−3.1% | Hold | +5.3% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $65.00 → $63.00−3.1% | Hold | +5.3% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $62.00 → $60.00−3.2% | Hold | +0.3% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $65.00 → $63.00−3.1% | Hold | +5.3% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $63.00 → $61.00−3.2% | Hold | +1.9% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | — | Buy | — | Reiterated | 10.09.26on TipRanks 08:45 | +0.7%next day −0.4% · 5 days +4.4% | ↗ |
| David Dai★★★★★★★★★★#2876 · hits 59% · avg +9.3% | UBS | $90.00 | Buy | +50.4% | Assigned | 21.08.26on TipRanks Aug 20 07:35 | −3.0%next day +2.4% · 5 days +0.7% | ↗ |
| Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% | Morgan Stanley | $93.00 | Buy | +55.4% | Assigned | 17.08.26on TipRanks 08:55 | +3.2%next day −0.4% · 5 days +2.6% | ↗ |
| Sam Slutsky★★★★★★★★★★#35 · hits 55% · avg +49.4% | LifeSci Capital | $108 | Buy | +80.5% | Reiterated | 07.08.26on TipRanks 11:27 | −0.3%next day +2.0% · 5 days −0.5% | ↗ |
| Kelsey Goodwin★★★★★★★★★★#203 · hits 68% · avg +62.4% | Piper Sandler | $82.00 → $85.00+3.7% | Buy | +42.0% | Reiterated | 07.08.26on TipRanks 08:01 | −0.3%next day +2.0% · 5 days −0.5% | ↗ |
| Alec Stranahan★★★★★★★★★★#1533 · hits 52% · avg +8.4% | Bank of America Securities | $87.00 → $88.00+1.1% | Buy | +47.0% | Reiterated | 07.08.26on TipRanks 06:50 | −0.3%next day +2.0% · 5 days −0.5% | ↗ |
| Andres Y. Maldonado★★★★★★★★★★#149 · hits 58% · avg +42.1% | H.C. Wainwright | $100 | Buy | +67.1% | Reiterated | 07.08.26on TipRanks Aug 6 16:39 | −0.3%next day +2.0% · 5 days −0.5% | ↗ |
| Joshua Schimmer★★★★★★★★★★#407 · hits 51% · avg +19.0% | Cantor Fitzgerald | $105 | Buy | +75.4% | Reiterated | 06.08.26on TipRanks Aug 7 09:06 | +3.5%next day −0.3% · 5 days −1.4% | ↗ |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $81.00 → $79.00−2.5% | Buy | +32.0% | Reiterated | 06.08.26on TipRanks Aug 7 07:06 | +3.5%next day −0.3% · 5 days −1.4% | ↗ |
| Boris Peaker★★★★★★★★★★#357 · hits 49% · avg +22.6% | JonesTrading | $85.00 | Buy | +42.0% | Reiterated | 06.08.26on TipRanks 17:31 | −0.3%next day +2.0% · 5 days −0.5% | ↗ |
| Kalpit Patel★★★★★★★★★★#1436 · hits 39% · avg +16.1% | Wolfe Research | — | Hold | — | Reiterated | 26.05.26on TipRanks 11:45 | −4.3%next day −1.7% · 5 days −11.5% | ↗ |
| Robert Driscoll★★★★★★★★★★#1346 · hits 46% · avg +10.6% | Wedbush | $80.00 | Buy | +33.7% | Reiterated | 18.05.26on TipRanks 08:15 | −5.9%next day +1.3% · 5 days −3.3% | ↗ |
| Brian Cheng★★★★★★★★★★#1122 · hits 55% · avg +14.0% | J.P. Morgan | $91.00 → $96.00+5.5% | Buy | +60.4% | Assigned | 11.05.26on TipRanks 09:20 | −0.7%next day +4.1% · 5 days −9.1% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | — | Buy | — | Reiterated | 11.05.26on TipRanks 07:06 | −0.7%next day +4.1% · 5 days −9.1% | ↗ |
| Bradley Canino★★★★★★★★★★#1614 · hits 46% · avg +10.8% | Guggenheim | $90.00 | Buy | +50.4% | Reiterated | 27.02.26on TipRanks Mar 2 07:01 | +5.3%next day −1.8% · 5 days +7.2% | ↗ |
| Corinne Johnson★★★★★★★★★★#1634 · hits 55% · avg +11.6% | Goldman Sachs | $55.00 → $82.00+49.1% | Buy | +37.0% | Reiterated | 12.01.26on TipRanks 16:34 | −1.9%next day +6.1% · 5 days +9.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering CG Oncology, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $92.56 at a price of $70.89 (+30.6%); now: $92.56 at $59.85 (+54.6%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 5 | 4 | 0 | 0 | 0 |
| Buy | 23 | 20 | 20 | 16 | 14 | 11 |
| Hold | 2 | 2 | 2 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 12.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.83 (from $-0.96 to $-0.66). Last quarter: $-0.90.
Sales
Next quarter’s sales estimate — $1M (from $0M to $1M). Last quarter: $1M.
Best top-analyst consensus in the sector · Healthcare
About CG Oncology, Inc.
- CEO: Arthur Kuan
- Employees: 142
- 3000 Pegasus Park Drive, Dallas, TX, 75247, US
- cgoncology.com
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Data from the stock’s TipRanks forecast page, read 70 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗